Anti-Obesity Drugs: Market Research Report

Date: January 5, 2014
Pages: 135
Price:
US$ 4,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AFE5927BCA1EN
Leaflet:

Download PDF Leaflet

Anti-Obesity Drugs: Market Research Report
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as -
  • Arena Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Novo Nordisk
  • Orexigen Therapeutics, Inc.
  • Rhythm Pharmaceuticals
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Anti-Obesity Therapeutics - A Significantly Underserved Market
Obesity: An Unmet Medical Need
Currently Available Drugs
List of Currently Available Drugs for the Treatment of Obesity
The United States – The Largest Obesity and Anti-Obesity Market
Europe – A Market with Vast Potential
Emerging Economies to Lead Growth

Table 1. Global Obesity Prevalence (2013): Percentage Share Breakdown of Obese Population by Leading Countries (includes corresponding Graph/Chart)

2.COMPETITIVE SCENARIO

Drug Withdrawals Alter Competition Metrics
Unfavorable Reimbursement Levels Hamper Growth
New Entrants to Induce Competition
Anti-Obesity Drugs Under Pipeline

3.MARKET TRENDS, DRIVERS AND CHALLENGES

Alarming Rise in Global Obesity Levels – The Major Growth Factor

Table 2. Classification of BMI
Table 3. Overweight and Obese Population (Millions) for 2013 in Select Geographic Regions (includes corresponding Graph/Chart)
Table 4. Global Obesity Levels by Leading Countries and Others (2013): Percentage Breakdown of Obese Population for the United States, India, China, Mexico, the United Kingdom, Germany, Spain, Australia, Canada, Japan, Greece, South Korea, Portugal, Slovakia, New Zealand, Finland, Switzerland, Ireland, and Others (includes corresponding Graph/Chart)
Table 5. Abdominal Obesity Prevalence (%) by Region and Gender (includes corresponding Graph/Chart)

Growing Emphasis on Metabolism
New Research Aids in Discovery of Novel Drugs
Cyclic Guanosine Monophosphate Signaling – The Future of Anti-Obesity Pharmacotherapy?
Childhood Obesity – A Market with Unmet Needs
Online Drug Stores Boost Sales
Barriers to Development of Effective Drugs
Regulatory Additions – A Barrier to Entry?
High Drug Development Costs – A Major Setback
Weight Loss Alternatives – A Market Dampener
Short Treatment Duration – A Major Limiting Factor for Market Growth
Product Labelling Could Deter Treatment Continuation

4.SELECT PIPELINE DRUG CANDIDATES

Orexigen Completes Phase 3 Clinical Trials for NB32
Empatic™ Completes Phase II
Zafgen Completes Phase II Trial of Beloranib
Novo Nordisk Completes Phase III trial of Liraglutide
Rhythm Pharmaceuticals Commences Phase 2 Trials for RM
University of Michigan to Commence Trial of Amlexanox in Treating Obesity

5.SELECT SCIENTIFIC BREAKTHROUGHS

Study Links PAR2 Protein Amount to Obesity
Scientists at Cambridge University Discover Hunger Gene
Ghrelin Hormone Linked to Hunger and Obesity

6.OBESITY – AN INTRODUCTION

Diagnosis of Obesity
BMI Calculation and Classification
Waist Circumference and BMI
Types of Obesity
Monogenic Obesity
Polygenic Obesity
Causes of Obesity
Unhealthy Eating Habits
Environmental and Genetic Factors
Sedentary Lifestyle
Alcohol Intake
Childhood Obesity
Psychological Factors
Pregnancy
Hormonal Disorders
Drugs
Aging
Risks Associated with Obesity

7.OBESITY TREATMENT

Dietary Therapy
Exercise Therapy
Behavior Therapy
Pharmacotherapy
Weight Loss Surgery
Invasive Vis-à-vis Non-invasive Procedures
A Brief Review of Select Invasive Procedures
Bariatric Surgery
Laparoscopic Adjustable Gastric Banding (LAGB)
Vertical Banded Gastroplasty (VBG)
Roux-en-Y Gastric Bypass Procedure (RYGB)
Lap-Band Procedure
Gastric Band Procedure
Gastric Bypass Procedure
Doudenal Switch
Prescription Drugs Vis-à-vis Non-Prescription Drugs

Table 6. Obesity Treatment Options and Corresponding Success Rate

8.ANTI-OBESITY DRUGS - AN INSIGHT

Introduction
Mechanism of Action
Review of Available Prescription Anti-Obesity Drugs
Phentermine
Orlistat
Belviq (Lorcaserin)
Phentermine/Topiramate Cocktail

Table 7. Global Anti-obesity Prescription Drugs Market (2012): Percentage Share Breakdown of Prescriptions by Physician Practices - Primary Care Physicians (PCP), Internal Medicine, Obstetrics/Gynecology, Endocrinology/Diabetes, Psychiatry/Neurology, Cardiology and Others (includes corresponding Graph/Chart)

9.RECENT INDUSTRY ACTIVITY

Novo Nordisk to Launch Anti-Obesity Drug in Mexico
Orexigen Optimistic of FDA Approval for Contrave
Arena Extends Belviq Distribution Agreement with Eisai
Sorrento Partners Scripps Research
MedImmune Partners NGM Biopharmaceuticals to Develop Anti-Obesity Therapy
Arena Launches Belviq
Kitozyme Signs Deal with Corona
GSK and Vanderbilt Sign Agreement for New Anti-Obesity Drug
ScinoPharm Signs Agreement for Contract Manufacturing
Vivus Launches Qsymis
ScinoPharm Enters Supply Deal with Vivus

10.FOCUS ON SELECT PLAYERS

Arena Pharmaceuticals, Inc. (US)
F. HOFFMANN-LA ROCHE LTD. (Switzerland)
GlaxoSmithKline Plc. (UK)
Novo Nordisk (Denmark)
Orexigen Therapeutics, Inc. (US)
Rhythm Pharmaceuticals (US)
VIVUS, Inc. (US)
Zafgen Inc. (US)

11.GLOBAL MARKET PERSPECTIVE

Table 8. World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 9. World Historic Review for Anti-Obesity Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 10. World 15-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. Market Analysis

Table 11. US Weight Loss Market by Major Product Segment (2013): Percentage Share Breakdown of Revenues for Diet Drinks, Health Clubs, Bariatric Surgery, Diet Foods, Artificial Sweeteners, Weight Loss Centers, Medically Supervised Programs, Meal Replacements & Appetite Suppressants, Prescription Drugs, Low Calorie Diet Programs, and Others (includes corresponding Graph/Chart)

Competitive Scenario
Obesity Catching Them Young

Table 12. US Childhood Obesity by Age-Group (2013): Percentage of Obese Population (includes corresponding Graph/Chart)

Penetration of Anti-Obesity Drugs Remains Poor
Key Statistics

Table 13. US Obesity Rates by Ethnicity for Men & Women: 2013 (includes corresponding Graph/Chart)
Table 14. Proportion (%) of Obesity in the US Overweight Population by Age Group (includes corresponding Graph/Chart)
Table 15. Obesity Prevalence in US Adults by Type (2013) (includes corresponding Graph/Chart)
Table 16. US Obesity Prevalence by Age-group: 2013 (includes corresponding Graph/Chart)
Table 17. US Obesity Prevalence by Annual Income Level (%): 2013 (includes corresponding Graph/Chart)

State-wise Stats

Table 18. US Obesity Prevalence by Top Cities (% of Total Population): 2013 (includes corresponding Graph/Chart)
Table 19. US Prevalence of Obesity by Top States (% of Total Population): 2013 (includes corresponding Graph/Chart)

Reimbursement Scenario
Regulatory Environment
High Development Costs – A High Entry Barrier for Drug Makers
Lack of Overall efficacy and outcomes data – A Dampener
Obesity and Related Ailments: Burden on Societal and Economic Costs
Product Launches
Strategic Corporate Developments
Select Key Players
B. Market Analytics

Table 20. The US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 21. The US Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

2.CANADA

Market Analysis

Table 22. Canadian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 23. Canadian Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3.JAPAN

Market Analysis

Table 24. Japanese Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 25. Japanese Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4.EUROPE

A. Market Analysis
Europe - an Opportune Market for Chronic Weight Management Drugs
Prevalence of Obesity in Europe

Table 26. Obese and Overweight & Obese Population in the European Union (2013): Percentage Share Breakdown by Age Group (includes corresponding Graph/Chart)
Table 27. Select EU Member Countries Ranked by Obesity Rates (2013): Percentage Share of Domestic Obese Population in Global Obese Population (includes corresponding Graph/Chart)
Table 28. Obesity Prevalence in Select EU Countries (2013) by Gender (%) (includes corresponding Graph/Chart)

B. Market Analytics

Table 29. European Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 30. European Historic Review for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
Table 31. European 15-Year Perspective for Anti-Obesity Drugs by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4A.FRANCE

A. Market Analysis
Changing Lifestyle Alters Health Profile
B. Market Analytics

Table 32. French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 33. French Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4B.GERMANY

A. Market Analysis
The Largest Anti-Obesity Market in Europe
B. Market Analytics

Table 34. German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 35. German Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4C.ITALY

Market Analysis

Table 36. Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 37. Italian Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4D.THE UNITED KINGDOM

A. Market Analysis
Anti-Obesity Drugs - the Need of the Hour as NHS Firefights Rising Peril of Obesity
GlaxoSmithKline Plc – A Key Player
Strategic Corporate Development
B. Market Analytics

Table 38. The UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 39. The UK Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4E.REST OF EUROPE

A. Market Analysis
Review of Select Markets
Spain
Belgium
The Netherlands
Finland
Sweden
Strategic Corporate Development
Key Players
B. Market Analytics

Table 40. Rest of European Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 41. Rest of European Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5.ASIA-PACIFIC

A. Market Analysis
Brief Review of Select Countries
Australia

Table 42. Australian Obesity & Overweight Prevalence (2013): Percentage Share Breakdown of Population for Obese/Overweight, Healthy Weight and Underweight Categories (includes corresponding Graph/Chart)

Historic Perspective:

Table 43. Prevalence Rate (%) of Overweight/Obese Students in Australia (includes corresponding Graph/Chart)

China
India
Korea
Use of Diet Pills Lack Proper Monitoring
New Zealand
Strategic Corporate Developments
B. Market Analytics

Table 44. Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 45. Asia-Pacific Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

6.LATIN AMERICA

A. Market Analysis
Mexico – A Review
B. Market Analytics

Table 46. Latin American Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 47. Latin American Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

7.REST OF WORLD

Market Analysis

Table 48. Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
Table 49. Rest of World Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 33 (including Divisions/Subsidiaries - 34)
The United States (14)
Japan (4)
Europe (8)
  The United Kingdom (3)
  Rest of Europe (5)
Asia-Pacific (Excluding Japan) (8)
Skip to top


World Anti-Obesity Drug Market 2011-2021 US$ 2,325.00 Feb, 2011 · 209 pages
Anti-Obesity Drugs Markets in China US$ 4,000.00 May, 2016 · 211 pages

Ask Your Question

Anti-Obesity Drugs: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: